Print

Salix Pharmaceuticals, Ltd. (SLXP) and Progenics Pharmaceuticals, Inc. (PGNX) Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients With Chronic Pain  
6/11/2013 10:11:06 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RALEIGH, N.C. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ:PGNX) today announced that the FDA is seeking input from an Advisory Committee on Salix's Supplemental New Drug Application (sNDA) for RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, for opioid-induced constipation, or OIC, in patients with chronic pain.

Help employers find you! Check out all the jobs and post your resume.

//-->